Heart Failure Clinical Trial
Official title:
Evaluation of Clinical Outcomes of Transseptal Transcatheter Mitral Valve-in-Valve Replacement for Degenerated Bioprostheses - The China Mviv Registry
NCT number | NCT05925335 |
Other study ID # | 2023YLK 21 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 11, 2023 |
Est. completion date | June 11, 2025 |
Mitral valve disease is the most common structure heart disease, and surgical valve replacement is an important treatment for severe mitral valve disease. There are 2 types of valve often been used, mechanical or biological protheses valves. Mechanical valve requires lifelong use of anticoagulants and take the risk of bleeding through all lifetime, but bioprotheses valve do not..
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 11, 2025 |
Est. primary completion date | July 11, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject had a degenerated surgical mitral bioprosthesis with at least moderate to severe mitral regurgitation or severe stenosis with echocardiographically derived mitral valve area (MVA) of =1.5 cm2 - Subjiect is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater. - Subject is at least 18 years old. - Heart team (including cardiac surgeon) agree on eligibility including assessment that transeptal, transcatheter mitral valve replacement (TsMVR) and redo surgical mitral valve replacement (rSMVR) are appropriate. - The study patient or the study patient's legal representative informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board (IRB) center. - The study Subject agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone/clinic follow-up. Exclusion Criteria: - Subject was operable with the assessment of experienced Heart Team - Subject had evidence of an acute MI, percutaneous intervention, or a peripheral intervention =30 days prior to Portico ViV index procedure. - Subject had uncontrolled blood dyscrasias defined as: leukopenia (WBC<3,000 mm3), acute anemia (Hb <9 g/dL), or thrombocytopenia (platelet count <50,000 cells/mm³). - Subject was considered hemodynamically unstable at the time of the ViV procedure (requiring inotropic support or mechanical heart assistance) - Subject had severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram. - Subject had imaging evidence of intracardiac mass, thrombus or vegetation. - Subject had an active peptic ulcer or has/had upper gastrointestinal (GI) bleeding =3 months prior to ViV index procedure. - Subject had a documented history of a cerebrovascular accident (CVA) or a transient ischemic attack (TIA) =6 months prior to index procedure. - Subject had active bacterial endocarditis or ongoing sepsis = 6 months prior to the index procedure. - Subject was unable to tolerate antiplatelet or anticoagulant therapy |
Country | Name | City | State |
---|---|---|---|
China | Yan Wang | Xiamen | Fujian |
Lead Sponsor | Collaborator |
---|---|
Xiamen Cardiovascular Hospital, Xiamen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | all-cause mortality | The rate in all-cause mortality will be calculated from 0 month to 12 months. | 12 months | |
Primary | Rate of New hospitalization for heart failure | Hospitalization for valve-related symptoms or worsening congestive heart failure | 12 months | |
Secondary | Technical success | Technical success was the primary safety endpoint at the time of patient exit from the cardiac catheterization laboratory, which was defined as the delivery and retrieval of the transcatheter delivery system being successful, the deployment of a single valve in the proper position in the mitral annulus, no need for surgery or additional reintervention, and the patient leaving the procedure room alive | 24 hours | |
Secondary | Procedure success | Procedure success defiened as adequate performance of the THV with residual MR grade < 2 and mean MV gradient (MVG) < 10 mm Hg. | 12 months | |
Secondary | all-cause mortality | The rate in all-cause mortality will be calculated from 0 month to 12 months. | annual for five years | |
Secondary | Rate of New hospitalization for heart failure | Hospitalization for valve-related symptoms or worsening congestive heart failure | annual for five years | |
Secondary | Rate of myocardial infarction | annual for five years | ||
Secondary | Rate of neurological events | All stroke, transient ischemic attack (TIA) | annual for five years | |
Secondary | Rate of Structural Valve dysfunction | as assessed by transthoracic echocardiography with residual MR grade > 2 and mean MV gradient (MVG) = 10 mm Hg. | annual for five years | |
Secondary | Clinical Benefit Endpoint | Change in New York Heart Association (NYHA) functional classification from baseline | 30 days, 6 months, 12 months, annual for five years] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|